Il Servizio

Il Servizio di Epidemiologia e Farmacologia Preventiva (SEFAP) ha come principali obiettivi:

a) La promozione e lo svolgimento di attività di ricerca nel campo di: studi epidemiologici di prevalenza e/o incidenza di fattori di rischio o di malattie nella popolazione o in gruppi selezionati della popolazione; studi di farmacoutilizzazione (profilo di utilizzo dei farmaci e appropriatezza prescrittiva); studi di farmacoepidemiologia e farmacovigilanza; sviluppo di indicatori di performance.
b) La collaborazione con enti sanitari locali e nazionali e aziende private.
c) La stimolazione di iniziative di cooperazione interdisciplinare.
d) L'organizzazione di un Master annuale di secondo livello in Farmacovigilanza.
e) La promozione di seminari, corsi di aggiornamento, nazionali ed internazionali su argomenti di interesse del Centro.
f) La promozione del dibattito scientifico sull'uso appropriato del farmaco, anche attraverso simposi, interventi educazionali e pubblicazioni scientifiche.
g) La pubblicazione di una rivista ad hoc, articoli, manoscritti, linee guida e indici bibliografici.

Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
Casula M, Scotti L, Tragni E, Merlino L, Corrao G, Catapano AL.
Atherosclerosis. 2016 Nov;254:172-178.Abstract

Statin use and risk of cataract: A nested case-control study within a healthcare database.
Casula M, Soranna D, Corrao G, Merlino L, Catapano AL, Tragni E.
Atherosclerosis. 2016 Aug;251:153-8.Abstract

A simple informative intervention in primary care increases statin adherence.
Casula M, Tragni E, Piccinelli R, Zambon A, De Fendi L, Scotti L, Corrao G, Gambera M, Catapano AL, Filippi A.
Eur J Clin Pharmacol. 2016 Feb;72(2):227-34. Abstract

Incretin-based drugs and risk of acute pancreatitis: a nested-case control study within a healthcare database.
Soranna D, Bosetti C, Casula M, Tragni E, Catapano AL, Vecchia CL, Merlino L, Corrao G.
Diabetes Res Clin Pract. 2015 May;108(2):243-9. Abstract

Are generic and brand-name statins clinically equivalent? Evidence from a real data-base.
Corrao G, Soranna D, Arfè A, Casula M, Tragni E, Merlino L, Mancia G, Catapano AL.
Eur J Intern Med. 2014 Oct;25(8):745-50. Abstract

Statins and the risk of diabetes: evidence from a large population-based cohort study.
Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, Tragni E, Casula M, Grassi G, Mancia G.
Diabetes Care. 2014 Aug;37(8):2225-32. Abstract

Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population.
Baragetti A, Palmen J, Garlaschelli K, Grigore L, Pellegatta F, Tragni E, Catapano AL, Humphries SE, Norata GD, Talmud PJ.
J Intern Med. 2015 Apr;277(4):478-87. Abstract

Assessment and potential determinants of compliance and persistence to antiosteoporosis therapy in Italy.
Casula M, Catapano AL, Piccinelli R, Menditto E, Manzoli L, De Fendi L, Orlando V, Flacco ME, Gambera M, Filippi A, Tragni E.
Am J Manag Care. 2014;20(5):e138-e145. Articolo

High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study.
Corrao G, Soranna D, Casula M, Merlino L, Porcellini MG, Catapano AL.
Atherosclerosis. 2014 Mar 15;234(1):224-229. Abstract

PTX3 Plasma Levels and Carotid Intima Media Thickness Progression in the General Population.
Baragetti A, Knoflach M, Cuccovillo I, Grigore L, Casula M, Garlaschelli K, Mantovani A, Wick G, Kiechl S, Willeit J, Bottazzi B, Catapano AL, Norata GD.
Nutr Metab Cardiovasc Dis. 2014 May;24(5):518-23. Abstract

Long-term use of statins reduces the risk of hospitalization for dementia.
Corrao G, Ibrahim B, Nicotra F, Zambon A, Merlino L, Scognamiglio Pasini T, Catapano AL, Mancia G.
Atherosclerosis. 2013 Oct;230(2):171-6. Abstract

Lower Rate of Cardiovascular Complications in Patients on Bolus Insulin Analogues: A Retrospective Population-Based Cohort Study.
Cammarota S, Falconio LM, Bruzzese D, Catapano AL, Casula M, Citarella A, De Luca L, Flacco ME, Manzoli L, Masulli M, Menditto E, Mezzetti A, Riegler S, Novellino E, Riccardi G.
PLoS One. 2013 Nov 7;8(11):e79762. Articolo

Prevalence of the Prescription of Potentially Interacting Drugs.
Tragni E, Casula M, Pieri V, Favato G, Marcobelli A, Trotta MG, Catapano AL.
PLoS One. 2013 Oct 11;8(10):e78827. Articolo

Different patterns characterize Omega 6 and Omega 3 long chain polyunsaturated fatty acid levels in blood from Italian infants, children, adults and elderly.
Risé P, Tragni E, Ghezzi S, Agostoni C, Marangoni F, Poli A, Catapano AL, Siani A, Iacoviello L, Galli C; on behalf of the IDEFICS Consortium and of the CHECK Group.
Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):215-20. Abstract

Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials.
Casula M, Soranna D, Catapano AL, Corrao G.
Atheroscler Suppl. 2013 Aug;14(2):243-51. Abstract

Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: A population-based cohort study in Italy.
Cammarota S, Bruzzese D, Catapano AL, Citarella A, De Luca L, Manzoli L, Masulli M, Menditto E, Mezzetti A, Riegler S, Putignano D, Tragni E, Novellino E, Riccardi G.
Nutr Metab Cardiovasc Dis. 2013 Jun 24. [Epub ahead of print]. Abstract

C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population.
Casula M, Tragni E, Zambon A, Filippi A, Brignoli O, Cricelli C, Poli A, Catapano AL.
Eur J Intern Med. 2013;24:161-166. Abstract

Risk factors distribution and cardiovascular disease prevalence in the Italian population: The CHECK study.
Tragni E, Filippi A, Casula M, Favato G, Brignoli O, Cricelli C, Poli A, Catapano AL.
OJEpi 2012; 2:90-100. Articolo

Adherence to lipid-lowering treatment: the patient perspective.
Casula M, Tragni E, Catapano AL.
Patient Prefer Adherence. 2012;6:805-814. Articolo

Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study.
Poli A, Casula M, Tragni E, Brignoli O, Filippi A, Cricelli C, Catapano AL.
Pharmacol Res. 2011 Oct;64(4):393-6. Abstract

Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases.
Corrao G, Scotti L, Zambon A, Baio G, Nicotra F, Conti V, Capri S, Tragni E, Merlino L, Catapano AL, Mancia G.
Atherosclerosis. 2011 Aug;217(2):479-85. Abstract

Distribuzione dei fattori di rischio e prevalenza delle malattie cardiovascolari nella popolazione italiana: lo studio CHECK (Cholesterol and Health: Evaluation, Control and Knowledge).
Tragni E, Filippi A, Casula M, Brignoli O, Cricelli C, Poli A, Catapano AL, per il gruppo CHECK.
Cardiorenal journal. 1 Jul 2011. [Epub ahead of print]. Articolo

Prescription of anti-osteoporosis drugs during 2006-2008 in an Italian local health unit.
Casula M, Filippi A, Decè F, Defendi L, Gandolfi L, Perego L, Piccinelli R, Catapano AL, Tragni E.
PharmacoEconomics – Italian Research Articles. 2010, Vol.12 (2): 71-131. Abstract

Blood pressure and anti-hypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK study.
Filippi A, Casula M, Tragni E, Brignoli O, Cricelli C, Poli A, Catapano AL for The CHECK Study Group.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):562-8. Abstract

How many patients need statin treatment in a low cardiovascular risk country? LDL-cholesterol target and distance from target distribution in an Italian cohort.
Poli A, Tragni E, Casula M, Filippi A, Diotti R, Brignoli O, Cricelli C, Catapano AL, for the CHECK Group.
Nutr Metab Cardiovasc Dis. 2012 Apr;22(4):327-36. Abstract

Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
Corrao G, Conti V, Merlino L, Catapano AL, Mancia G.
Clin Ther. 2010 Feb;32(2):300-10. Abstract

Effect of Age and Sex Related Therapeutic Needs on General Practices' Prescribing Cost: The ASSET (Age/Sex Standardised Estimates of Treatment) Research Model.
Favato G, Mariani P, Print CF, Capone A, Pelagatti MM, Pieri V, Marcobelli A, Tragni E, Trotta G, Zucchi A, Catapano AL.
Pharmacoeconomics - Italian Research Articles 2008; 10(2):89-98. Abstract

Risk Factors Distribution and Cardiovascular Disease Prevalence in a Representative Sample of Italian Population: The Check Study.
Brignoli O, Casula M, Catapano AL, Cricelli C, Favato G, Filippi A, Poli A, Tragni E.
Working paper available at http://ssrn.com. Date posted: December 01, 2008; Last revised: March 30, 2010. Articolo

Lo studio CHECK (Cholesterol and Health: Evaluation, Check e Control): Distribuzione dei fattori di rischio e prevalenza delle malattie cardiovascolari in un campione rappresentativo della popolazione italiana.
Tragni E, Filippi A, Casula M, Brignoli O, Cricelli C, Poli A, Catapano AL.
Atherosclerosis Update 2008; n. 1. Articolo

ASSET (Age/Sex Standardised Estimates of Treatment): a research model to improve the governance of prescribing funds in Italy.
Favato G, Mariani P, Mills RW, Capone A, Pelagatti M, Pieri V, Marcobelli A, Trotta MG, Zucchi A, Catapano AL.
PLoS One. 2007 Jul 4;2(7):e592. Abstract

Monitoring statin safety in primary care.
Tragni E, Filippi A, Mazzaglia G, Sessa E, Cricelli C, Catapano AL.
Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):652-7. Abstract

Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice.
Filippi A, Tragni E, Bignamini AA, Sessa E, Merlini G, Brignoli O, Mazzaglia G, Catapano AL.
Eur J Cardiovasc Prev Rehabil. 2005 Apr;12(2):159-63. Abstract

Achievement of the therapeutic goals for dyslipidemia in clinical practice: results of a survey among general practice physicians from Lombardy.
Tragni E, Catapano AL, Bertelli A, Poli A.
Ital Heart J. 2003 Dec;4 Suppl 7:47S-57S. Italian. Abstract

La dislipidemia.
Catapano AL, Poli A, Tragni E.
4° Rapporto sull’Obesità in Italia, Istituto Auxologico Italiano, Milano 2002.

Ipercolesterolemia e malattia coronarica: dati italiani ed internazionali.
Catapano AL, Poli A, Tragni E.
The Journal of the Italian College of General practitioners, 2001; 5:6-9. Articolo

Low density lipoprotein oxidation, antioxidants, and atherosclerosis.
Catapano AL, Maggi FM, Tragni E.
Curr Opin Cardiol. 2000 Sep;15(5):355-63. Abstract

Rischio cardiovascolare, ipercolesterolemia e malattia coronarica: dati italiani e dati internazionali.
Catapano AL, Poli A, Tragni E.
Annali Italiani di Medicina Interna, 2000; 15 suppl. 1:51S-54S.

Modalità di refertazione dei lipidi plasmatici: indagine tra i laboratoristi delle società SIBioC e SIMeL
Catapano AL, Tragni E, Galli G, Brambilla S, Lippi U, Franzini C.
Rivista di Medicina di Laboratorio, 2000; 1:1-90. Articolo

Valori ideali o valori di riferimento per i lipidi del plasma. Risultati di una indagine (1999) tra i laboratori italiani.
Catapano AL, Tragni E, Galli G, Brambilla S, Lippi U, Franzini C.
Biochimica Clinica, 2000, 24: 10-19. Articolo

Valori di colesterolemia nella popolazione di differenti regioni italiane: risultati di una indagine 1999.
Franzini C, Brambilla S, Luraschi P, Tragni E, Galli G, Catapano AL.
Biochimica Clinica, 2000, 24:20-26. Articolo

Relationship between hypercholesterolemia and coronary disease: Italian data and international data.
Catapano AL, Poli A, Tragni E.
Cardiologia. 1999 Dec;44 Suppl 1(Pt 2):869-73. Italian. Abstract

Antioxidants and coronary artery disease.
Catapano AL, Tragni E.
Curr Atheroscler Rep. 1999 Nov;1(3):221-9. Abstract

Recenti linee guida per il trattamento delle dislipidemie e dell’ipertensione nella prevenzione delle malattie cardiovascolari.
Catapano AL, Poli A, Tragni E.
Annali di Medicina Interna, 1999, 14 suppl. 1:57S-64S.